Anticoagulation is an effective means of preventing the majority of ischaemic strokes in patients with non-valvular atrial fibrillation (NVAF). This 4-part series examines oral anticoagulation in NVAF, explores the rationale for urgency in anticoagulation and the important role played by the GP, evaluates the efficacy and safety of the NOACs and explores the GP’s role in optimising medication compliance and adherence and then uses a case study to explore important issues around OAC optimisation.
This activity has been approved by The Royal Australian College of General Practitioners QI&CPD Program.
On completion of this program, participants will be better able to:
- Describe the evidence on stroke prevention with non-vitamin K antagonist oral anticoagulants (NOACs) and proactively engage patients with non-valvular atrial fibrillation (NVAF) in conversation about oral anticoagulant treatment options
- Interpret the real world safety evidence for the NOACs as it pertains to patient populations
- Assess the impact of patient concerns regarding bleeding in management of AF, and the role of NOAC reversing agents in emergencies
- Engage in shared decision-making that aims to improve adherence to oral anticoagulation therapy, and thereby optimising patient outcomes